Institution identification

Institution ID

5589

Institution full name and acronym

Optum

Institution countries

Germany

Type of institution

Other

Institution website

ENCePP partner

Yes
Institution description
Optum is a member of the UnitedHealth Group family of companies. Optum is specialized in the conduct of late phase research,PASS,health economics & outcomes research,patient reported outcomes research & market access & reimbursement. Optum was orginally named Ingenix & was formed in 1999 to create the industry's leading health data & information firms combined into one organization. Optum is among the largest health information & data company in the world. Optum provides knowledge & information services to physicians & health care professionals,health insurers,employers & health care buyers,pharmaceutical & biotechnology companies,medical device manufacturers,& government entities. Optum offers a wide range of services to the pharmaceutical industry,including clinical trial,safety,epidemiology & pharmacoeconomic studies using administrative claims data. Optum offers a variety of data products to provide market-based answers to specific questions.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A retrospective longitudinal cohort study assessing the safety of Seasonique® use: A post-marketing authorization safety study (PASS) to assess the risk of venous thromboembolic events (VTE) in women exposed to Seasonique®
A Study of Treatments for Overactive Bladder: Incidence and Validation of Cardiovascular and Cancer Outcomes and Examination of Drug-Use Patterns in a US Health Care Claims Data Environment (OAB)
An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using Health Insurance Databases in the United States
Assessment of risk factors for Myocarditis in the United States (US) using Electronic Health Records and Claims data
FINErenone druG Utilization Study and assessment of Temporal changes following availability of different treatment options in patients with chronic kidney disease and type 2 diabetes (FINEGUST)
Hepatic Outcomes Among Adults Taking Duloxetine in a US Health Care Claims Database (F1J-MC-B037)
Incidence of Pancreatic Malignancy and Thyroid Neoplasm in Type 2 Diabetes Mellitus Patients who Initiate Exenatide Compared to Other Antihyperglycemic Drugs - Phase 2 (Extended Accrual and Follow-Up)
Incidence of Pancreatic Malignancy and Thyroid Neoplasm in Type 2 Diabetes Mellitus Patients who Initiate Exenatide Compared to Other Antihyperglycemic Drugs. (B015)
Multisource Surveillance Study of Pregnancy and Infant Outcomes in Ocrelizumab-Exposed Women With Multiple Sclerosis (MELODIC Study)
Observational Secondary Database Study to Assess the Long-Term Safety of Mirikizumab (I6T-MC-B004)
Observational Study of Effectiveness and Safety of Recombinant Zoster Vaccine (Shingrix)® in Moderately-to-Severely Active Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) Patients Treated with Tofacitinib (Xeljanz)® in Real- World Clinical Care Settings
One Year Post-discharge Clinical and Economic Outcomes among Patients with ACS Managed with PCI and Treated with Prasugrel versus Clopidogrel (H7T-MC-B022)
Ozanimod Real-World Safety - A Post-Authorisation Multi-National Long-term Non-Interventional Study (ORION)
Post-authorization Safety Study Evaluation of Cardiovascular Events in Users of Mirabegron and Other Treatments for Overactive Bladder
Post-authorization Safety Study Evaluation of Neoplasm Events in Users of Mirabegron and Other Treatments for Overactive Bladder : Core Common Protocol
Postmarketing commitment safety study of HZ/su to evaluate pregnancy exposures and outcomes in immunodeficient or immunosuppressed women between 18 and 49 years of age (EPI-ZOSTER-039 VS US DB 214420)
Postmarketing Noninterventional Study Evaluating the Risk of Endometrial Cancer in Women Who Have Been Prescribed Imvexxy®
Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
Risk Prediction, Prognosis and Management of Cardiac Events among Patients with Multiple Myeloma (20160220)